BSBaixin Shen

Baixin Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Baixin Shen has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Zhengsen Chen

    Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, China

    6 shared publications
  • Zongyao Fan

    Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

    5 shared publications
  • Junjie Zhang

    Department of Urology, the Second Affiliated Hospital of Nanjing Medical University, Nanjing, China

    4 shared publications
  • Qingyu Ge

    Urology Centre, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China

    4 shared publications
  • Hewei Xu

    Department of Urology, Children’s Hospital of Nanjing Medical University, Nanjing, 210000, People’s Republic of China

    3 shared publications
  • Tianpeng Du

    Department of Urology, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, 210000, People’s Republic of China

    3 shared publications

Latest Publications

  • Open Access

    Wnt11 mediates fibroblast–smooth muscle cell interaction to promote neurogenic bladder fibrosis in rats

    by Qingyu Ge, Junjie Zhang, Zongyao Fan, Yan Wang, Xinglin Chen, Dongdong Guo, Tao Wang, Cheng Ma, Xinyu Zhai, Guanqun Ju, et al.

    Neurogenic bladder (NB) is a lower urinary tract dysfunction caused by lesions in the nervous system that regulate urine storage and micturition. Fibrosis is considered the basic pathological alteration of NB, whereas the underlying mechanism remains unclear. Here, we find that Wnt11 is significantly up-regulated in the rat fibrotic bladders induced by bilateral pelvic nerve injury (BPNI) and spinal cord injury (SCI) and promotes bladder fibroblasts (BFs)-to-myofibroblasts transition and smooth muscle cells (SMCs) phenotypic transformation. Selective inhibition or gene silencing of Wnt11 in vivo and in vitro attenuates BFs and SMCs activation, and mitigates the development of NB fibrosis. Mechanistically, Wnt11 specifically binds to Vangl2 receptor to activate downstream JNK/c-JUN signaling via the membrane recruitment of DVL2. Further research shows that Wnt11 signaling interacts with transforming growth factor beta 1 (TGF-β1)/Smad-dependent pathway through the binding of membrane receptors (Vangl2 and TβR1) and the crosstalk of nuclear transcription factors. These findings uncover the regulatory mechanism and may provide a new therapeutic strategy for NB fibrosis.


  • Open Access

    Chemotherapy sequential disitamab vedotin in combination with tislelizumab as systemic therapy of upper tract urothelial carcinoma with cutaneous metastasis: A case report and literature review

    by Kangyu Liu, Ming Zheng, Lei Li, Mingyue Liang, Qingyi Zhu, Min Gu, Baixin Shen

    Rationale: To investigate the clinical features, management strategies, and prognosis of the rare condition of upper tract urothelial carcinoma (UTUC) with skin metastasis, with emphasis on the efficacy and safety of disitamab vedotin combined with tislelizumab in systemic therapy, we performed a literature search and selection. We searched PubMed, Embase, and Web of Science for English-language publications from January 1, 1990, through December 10, 2024 (last search December 10, 2024). Predefined terms combined “upper tract urothelial carcinoma” or “UTUC” with “skin,” “cutaneous,” “abdominal wall,” or “port-site,” and with “metastasis,” “implantation,” or “seeding.” Inclusion criteria were human case reports or small series with histologically confirmed UTUC and cutaneous involvement. We excluded non-UTUC primaries, noncutaneous metastases, pure reviews without primary cases, duplicate reports, and articles lacking extractable case-level clinical or pathologic data. Two reviewers independently screened records and extracted data (patient and tumor features, site and timing of cutaneous involvement, other metastases, postdiagnosis treatment, and outcomes), resolving discrepancies by consensus. Owing to rarity and heterogeneity, we performed a qualitative descriptive synthesis without meta-analysis. Patient concerns: A patient developed a progressively enlarging cutaneous mass on the abdominal wall at a prior laparoscopic port site following renal cyst surgery. Diagnoses: Biopsy confirmed metastatic poorly differentiated urothelial carcinoma. On April 27, 2023, the patient underwent robot-assisted radical nephrectomy with abdominal wall tumor resection and latissimus dorsi myocutaneous flap transfer. Postoperative pathology revealed high-grade urothelial carcinoma with human epidermal growth factor receptor 2 (+++) expression. Interventions: Gemcitabine/cisplatin was administered initially; however, due to intolerance to cisplatin-based chemotherapy, sequential disitamab vedotin (120 mg every 3 weeks) plus tislelizumab (200 mg every 3 weeks) was initiated on November 23, 2023. Outcomes: At 24-month postoperative follow-up, there was no evidence of local recurrence at the surgical site. Lessons: Cutaneous metastasis in UTUC is rare and portends a poor prognosis. Radical surgery combined with systemic therapy remains the cornerstone of care. In this case, disitamab vedotin plus tislelizumab, used as a postoperative sequential systemic regimen, demonstrated favorable safety and achieved a 24-month recurrence-free interval after discontinuation of gemcitabine/cisplatin due to intolerance, with manageable adverse effects. This combination may represent a potential treatment option for metastatic UTUC, although its efficacy requires validation in larger cohorts.

  • H3K9 lactylation drives FTO-mediated NRF2 suppression to exacerbate bladder epithelial ferroptosis and inflammation in diabetic bladder dysfunction

    by Zongyao Fan, Bin Ni, Zheng Duan, Feng Ling, Junjie Zhang, Jiayin Sun, Hao Yu, Jie Xu, Zhengsen Chen, Baixin Shen, et al.


  • Open Access

    NRF2 Deficiency in Bladder Epithelial Cells Owing to Ubiquitination by N6-Methyladenosine-Modified TRIM21 Induces Oxidative Stress and Inflammation to Aggravate IC/BPS

    by Zongyao Fan, Qingyu Ge, Bin Ni, Junjie Zhang, Tianpeng Du, Hewei Xu, Zheng Duan, Sicong Zhang, Chao Wang, Jun Xue, et al.

    Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) has become a pressing clinical issue due to its unclear etiology and severe, persistent pelvic pain. Despite extensive research, the pathogenesis of IC/BPS remains unresolved, and current treatments primarily target symptom relief rather than addressing underlying disease mechanisms. This study aimed to investigate the effects of nuclear factor erythroid 2-related factor 2 (NRF2) on IC/BPS and the potential molecular mechanisms. Methods: Bladder mucosal biopsies from IC/BPS patients were subjected to RT-qPCR and immunoblotting to quantify NRF2 mRNA/protein expression. In vivo modeling, WT and NRF2 gene knockout mice received intraperitoneal cyclophosphamide to induce cystitis. Bladder function was assessed via Void Spot Assays, and Urodynamic. In vitro validation, LPS-stimulated SV-HUC-1 cells were transduced with NRF2 knockdown or overexpression, and oxidative stress and inflammation levels were evaluated. Then, the molecular mechanism of NRF2 in IC/BPS was determined by conducting Western blot, mass spectrometry, co-immunoprecipitation, and RT-qPCR analyses. Results: This study identified markedly reduced expression of NRF2 in the lesional bladder mucosa of patients with IC/BPS. By employing NRF2 knockout mice and cellular models of bladder inflammation, the essential role of NRF2 in modulating oxidative stress and inflammation was underscored. Furthermore, tripartite motif-containing 21 (TRIM21) interacted with NRF2, promoting its degradation via ubiquitination in bladder epithelial cell lines, thus elucidating TRIM21’s regulatory role in bladder inflammation. Additionally, N6-methyladenosine (M6A) modifications recognized by IGF2BP2 enhanced TRIM21 expression by stabilizing TRIM21 mRNA. Conclusion: This study positions the TRIM21-NRF2 axis as a key regulator of oxidative stress and inflammation in IC/BPS and suggests it as a promising therapeutic target for future IC/BPS interventions.


  • Open Access

    Rictor Ameliorates Acute Antibody‐Mediated Rejection Following Kidney Transplantation by Suppressing Macrophage M1 Polarization Through p65‐NLRP3 Axis

    by Bin Ni, Chengcheng Yang, Junqi Zhang, Zhou Hang, Ming Zheng, Dengyuan Feng, Qinghuan Shen, Jinxu Miao, Xulin Sun, Li Sun, et al.

    Antibody‐mediated rejection (ABMR) represents the leading cause of kidney allograft failure over a long term after transplantation. Early infiltration of macrophages predicts the adverse outcome of grafts, yet the underlying mechanisms remain to be elucidated. Significant infiltration of M1 macrophages and upregulation of Rictor in macrophages are observed in ABMR allografts. Deficiency of Rictor in macrophages exacerbates histological injury and shortens the survival of ABMR allografts by promoting macrophage M1 polarization. Additionally, loss of Rictor in primary bone marrow‐derived macrophages facilitates NLRP3 inflammasome activation through activating NF‐κB. Mechanistically, Rictor upregulates E3 ubiquitin ligase SOCS1 to enhance K48‐linked ubiquitination of p65, thereby suppressing macrophage M1 polarization. Taken together, Rictor ameliorates acute ABMR following kidney transplantation by suppressing macrophage M1 polarization through the p65‐NLRP3 axis and may serve as a therapeutic target for ABMR.


  • Open Access

    Inhibition of HPSE/SDC-2 axis-induced epithelial-mesenchymal transition for treating IC/BPS

    by Zhengsen Chen, Yuting He, Junjie Zhang, Qingyu Ge, Tianpeng Du, Zongyao Fan, Junyl Zhou, Xin Yang, Baixin Shen, Zhongqing Wei

    Interstitial cystitis/bladder pain syndrome (IC/BPS) plagues patients and clinicians with its unclear etiology and pathogenesis, and ineffective treatments. Destruction of epithelial tissue and proliferation of interstitial tissue are typical pathological features of IC/BPS, in which epithelial-mesenchymal transition (EMT) may play an important role. Both the increased urination frequency observed in mice with acute cystitis induced by cyclophosphamide (CYP) and the disruption of the anti-leakage barrier in urothelial cells induced by LPS are associated with the occurrence of EMT. The expression of heparanase 1 (HPSE) and syndecan-2 (SDC-2) is up-regulated in the bladder mucosa of patients with IC, and both of them can promote the development of EMT. Improvement of lower urinary tract symptoms and restoration of the uroepithelial cell anti-leakage barrier in mice with CYP-induced cystitis after treatment with the HPSE inhibitor OGT2115 and inhibited the development of EMT. We then verified that HPSE binds to SDC-2 and that SDC-2 is a key intermediate protein in the pro-EMT role of HPSE, and that EMT was inhibited by knockdown of SDC-2. SDC-2 exerts its biological function by inhibiting the ubiquitinated degradation of TGF-βR1. Here we identified a novel mechanism by which the HPSE/ SDC-2 axis promotes EMT development and thus causes epithelial dysfunction and altered voiding behavior, providing a new direction for the treatment of IC/BPS.

  • Open Access

    SPHK1/S1PR1/PPAR-α axis restores TJs between uroepithelium providing new ideas for IC/BPS treatment

    by Junjie Zhang, Qingyu Ge, Tianpeng Du, Yuhao Kuang, Zongyao Fan, Xinyi Jia, Wenjin Gu, Zhengsen Chen, Zhongqing Wei, Baixin Shen

    Interstitial cystitis/bladder pain syndrome (IC/BPS) represents a chronic, aseptic inflammatory bladder condition with an unclear etiology and few therapeutic options. A composite barrier structure composed of the uroepithelium and glycosaminoglycan layer forms on the bladder’s inner surface to block urine and other harmful substances. Dysfunction of this barrier may initiate the pathogenesis of IC/BPS. Sphingosine-1-phosphate (S1P) plays a crucial role in forming tight junctions. Perfusion of S1P into the bladder restored uroepithelial tight junctions in mice with cyclophosphamide-induced acute cystitis and ameliorated symptoms of the lower urinary tract. Mice lacking sphingosine kinase 1 (SHPK1) exhibited more severe bladder injuries and dysfunction. Concurrent in vitro experiments elucidated S1P’s protective effects and its role as a primary messenger through SPHK1 and S1P receptor 1 (S1PR1) knockdown. This study identifies a novel mechanism whereby S1P binding to S1PR1 activates the PPAR-α pathway, thereby enhancing cholesterol transport and restoring tight junctions between uroepithelial cells. These findings elucidate the regulatory role of S1P in the bladder epithelial barrier and highlight a promising therapeutic target for IC/BPS.


  • Open Access

    Combined Signature of the Urinary Microbiome and Metabolome in Patients With Interstitial Cystitis

    by Hewei Xu, Nebiyu Elias Tamrat, Jie Gao, Jie Xu, Yiduo Zhou, Sicong Zhang, Zhengsen Chen, Yunpeng Shao, Liucheng Ding, Baixin Shen, et al.

    Interstitial cystitis (IC) is a clinical syndrome characterized by frequency, urgency, and bladder pain or pelvic pain; however, the underlying pathophysiological mechanisms and diagnostic markers are unknown. In this study, microbiome and metabolome analysis were used to explain the urine signatures of IC patients. Urine samples from 20 IC patients and 22 control groups were analyzed by using 16S rRNA sequence and liquid chromatography coupled with mass spectrometry. Four opportunistic pathogen genera, including Serratia, Brevibacterium, Porphyromonas, and Citrobacter, were significantly upregulated in IC group. The altered metabolite signatures of the metabolome may be related to sphingosine metabolism, amino acid metabolism, and fatty acid biosynthesis. Meanwhile, the associations were observed between different metabolites and microbiomes of IC. The present study suggests that the combined signatures of IC in urine microbiome and metabolome may become its prospective diagnostic markers.


  • Open Access

    Nrf2 Pathway Ameliorates Bladder Dysfunction in Cyclophosphamide‐Induced Cystitis via Suppression of Oxidative Stress

    by Bin Ni, Zhengsen Chen, Le Shu, Yunpeng Shao, Yi Huang, Nebiyu Elias Tamrat, Zhongqing Wei, Baixin Shen

    Objective. To investigate the protective effect and molecular mechanism of nuclear factor E2‐related factor 2 (Nrf2) pathway in interstitial cystitis (IC). Methods. We established a mouse model of IC by cyclophosphamide (CYP) in wild‐type mice and Nrf2 gene knockout mice. We examined the histological and functional alterations, the changes of oxidative stress markers, and the expression of the antioxidant genes downstream of Nrf2 pathway. Results. After CYP administration, the mice showed urinary frequency and urgency, pain sensitization, decreased contractility, bladder edema, and oxidative stress disorder. Notably, the Nrf2-/- CYP mice had more severe symptoms. The mRNA and protein levels of antioxidant genes downstream of Nrf2 pathway were significantly upregulated in the Nrf2+/+ CYP mice, while there were no significant changes in the Nrf2-/- CYP mice. Conclusion. Nrf2 pathway protects bladder injury and ameliorates bladder dysfunction in IC, possibly by upregulating antioxidant genes and inhibiting oxidative stress.


  • Open Access

    Primary bladder mucosa-associated lymphoid tissue lymphoma

    by Hewei Xu, Zhengsen Chen, Baixin Shen, Zhongqing Wei

    Introduction: Primary bladder mucosa-associated lymphoid tissue (MALT) lymphoma is a rare tumor. To date, the PubMed database contains only 39 English articles covering 63 cases of primary bladder MALT lymphoma. Herein, we report a case of this disease and review the current literature. Patient concerns: A 77-year-old woman presented with frequent urination, urinary urgency, and dysuria for 3 years. In the past 3 years, the patient's symptoms recurred and progressively worsened, and she was admitted to the hospital. Diagnosis: A histopathological examination revealed the bladder mass as a tumor with high proliferation of atypical B-lymphocytes. Immunohistochemistry showed positive results for CD20, PAX-5, Ki-67, BCL-2, and CD21 and negative results for CD10, MUM1, TDT, and cyclin D1. These data supported the diagnosis of primary bladder MALT lymphoma. Interventions: A transurethral resection of bladder tumor was performed to treat the disease. Outcomes: The patient was alive and healthy at the 15-month follow-up. Conclusion: Primary bladder MALT lymphoma is a rare disease and can be easily missed or misdiagnosed before achieving a histological confirmation. Surgery may be the best choice for both diagnosis and treatment.